Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron (NASDAQ: REGN) reached an agreement with the U.S. government on April 23, 2026 to lower certain drug prices and expand access. Key terms include free U.S. access to Otarmeni, lowering Medicaid prices tied to other developed countries, aligning future U.S. prices to that country group, Praluent availability via TrumpRx.gov, three years of tariff relief, and a >$9 billion U.S. manufacturing and R&D investment commitment.
Regeneron (NASDAQ: REGN) announced FDA accelerated approval of Otarmeni (lunsotogene parvec-cwha), the first and only gene therapy for OTOF-related severe-to-profound sensorineural hearing loss, indicated for pediatric and adult patients with molecularly confirmed biallelic OTOF variants. Regeneron will provide Otarmeni for free in the U.S.
Approval was based on CHORD trial results showing 80% primary-endpoint responders at 24 weeks and 42% of evaluable participants achieving normal hearing at longer follow-up; continued approval may require confirmatory trial data.
Regeneron (NASDAQ: REGN) and Sanofi announced FDA approval of Dupixent (dupilumab) for children aged 2–11 with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamines.
The approval, effective April 22, 2026, is based primarily on the LIBERTY-CUPID program and includes pharmacokinetic data from a single-arm pediatric trial; safety was consistent with prior indications.
Regeneron (NASDAQ: REGN) reported Phase 3 NIMBLE results for cemdisiran showing rapid, deep and sustained disease control in generalized myasthenia gravis (gMG) with subcutaneous dosing every 12 weeks.
At week 24 cemdisiran vs placebo showed a 2.3-point placebo-adjusted MG-ADL improvement (p<0.001) and a 2.8-point placebo-adjusted QMG improvement (p=0.002). U.S. regulatory application submitted Q1 2026; EU filings planned for 2026.
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in May and June 2026. Sessions are scheduled for BofA Securities Health Care Conference on May 12, 2026 at 10:00 a.m. PT (1:00 p.m. ET) and Goldman Sachs Global Healthcare on June 8, 2026 at 2:00 p.m. ET.
Webcasts, replays, and transcripts will be available via the company's Investors & Media page and archived for at least 30 days.
Regeneron (NASDAQ:REGN) and Telix announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies on a 50/50 cost and profit-sharing basis.
Key terms include a $40 million USD upfront payment to Telix for four initial programs, optional expansion to additional programs, potential aggregate milestone payments up to $2.1 billion USD, low double-digit royalties, and joint development of radio-diagnostics to support patient selection and response assessment.
Regeneron (NASDAQ: REGN) and Sanofi announced that the European Commission approved Dupixent (dupilumab) for treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2–11 years with inadequate response to H1 antihistamines and naïve to anti-IgE therapy.
The approval relies on the LIBERTY-CUPID program, combining adult Phase 3 efficacy data and pediatric CUPIDKids safety and pharmacokinetic data, and expands Dupixent's EU pediatric indications to under 12 across four type 2 inflammation diseases.
Regeneron (NASDAQ: REGN) announced a strategic collaboration with TriNetX to access TriNetX’s de-identified EHR network of approximately 300 million patients (about 170 million in the U.S.). Regeneron gains an exclusive opportunity to link RGC genomic and proteomic cohorts to this phenotypic dataset.
The deal enables expansion of Regeneron Genetics Center’s EHR-linked database, supports AI training for digital health solutions, and includes a Regeneron investment of up to $200 million. Data matching will follow applicable privacy laws including HIPAA and GDPR.
Regeneron (NASDAQ: REGN) announced FDA approval extending EYLEA HD (aflibercept) dosing intervals up to every 20 weeks (≈5 months) for wAMD and DME after one year of successful response, based on 96-week data from pivotal PULSAR and PHOTON trials.
Of patients completing week 96, 71% (wAMD) and 72% (DME) reached ≥16-week intervals; 47% (wAMD) and 44% (DME) reached ≥20-week intervals. Label now includes 96-week efficacy and safety; prefilled syringe review has an April 2026 target action date.
Regeneron (NASDAQ: REGN) will report first quarter 2026 financial and operating results on Wednesday, April 29, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 AM ET that day.
According to the company, the webcast will be available on its Investors and Media page and telephone participation requires advance registration; a replay and transcript will be archived on the company website for at least 30 days.